Table 1 Demographic and initial clinical assessments
Methotrexate n = 117Methotrexate ciclosporin n = 119Methotrexate prednisolone n = 115Triple therapy n = 116
Mean age (range)54 (21–80)53 (20–89)54 (27–84)55 (20–78)
Sex (F/M)78/3979/4090/2578/38
Rheumatoid factor positive76 (66%)77 (65%)76 (66%)83 (72%)
Rheumatoid arthritis nodules27 (23%)38 (32%)20 (17%)18 (16%)
Mean disease duration in months (SD)2.7 (3.8)4.2 (5.7)5.1 (5.8)3.9 (5.2)
Previous DMARDs14 (12%)17 (14%)16 (14%)18 (16%)
Mean DAS28 (SD)5.8 (1.2)5.9 (1.3)5.8 (1.4)5.6 (1.3)
Erosive changes on x-rays37 (32%)44 (37%)34 (30%)39 (34%)
Median Larsen score (IQR)7 (3, 15)8 (3, 23)6 (2, 20)5 (2, 14)
Mean HAQ (SD)1.5 (0.7)1.7 (0.7)1.6 (0.7)1.6 (0.7)
Median SF-36 PCS (IQR)30 (9)29 (8)30 (10)30 (9)
  • Mean values (SD) or median values with IQRs are shown.

  • IQRs, interquartile ranges; DMARDs, disease modifying anti-rheumatic drugs; HAQ, Health Assessment Questionnaire; SF-36 PCS, Short-Form Physical Component Summary; DAS28, Disease Activity Score including a 28-joint count.